|
 |
L-arginine
is considered the most potent free form amino acid ever discovered,
due to its powerful health properties, and is referred to
by scientists as the “Miracle Molecule.”
The remarkable properties of L-arginine were validated by
the 1998 Nobel Prize in Medicine, and since then have created
a frenzy of interest in the pharmaceutical and nutraceutical
fields.
Columbia University refers to L-arginine
as the “Magic Bullet”
in human health. Over 10,000 L-arginine
citations have been compiled by Columbia University researchers
in their quest to document the benefits of this simple amino
acid. |
|
It is now taught to medical students at the Columbia University
College of Physicians and Surgeons.
The Nobel Prize landmark discovery of the functions of nitric oxide
(NO) highlighted the fact that without NO, human life would be impossible.
Even more revolutionary was the irrefutable evidence that L-arginine
is the sole NO molecule in the human body.
Twenty years ago, the idea that a simple and humble amino acid could
change the face of medicine would have been dismissed. Now, physicians,
researchers, and scientists are embracing the effectiveness of L-arginine
and its use has become mainstream. |
 |
Incorrect
ingredients in L-arginine products will block L-arginine’s
entry into the body as a free form amino acid. If L-arginine is
not properly formulated, it will not elevate serum levels of L-arginine,
will not cross the Blood-Brain-Barrier (BBB), and will not provide
health benefits. L-arginine products that are founded on metabolic
mistakes do not metabolize correctly, and are therefore ineffective.
It is unwise to use any L-arginine product without first ascertaining
its length of use (history and use in humans), the formulator of
the product, the patent status, the form of L-arginine used, the
exclusion of L-arginine antagonists, and its ultimate isoform pathway
via inclusion of a “Blind Amino Acid Rider.”
Because all forms of L-arginine are Blind Amino Acids, it is mandatory
that the form of L-arginine be bound to a Blind Amino Acid Rider,
and formulated by an L-arginine expert with a background in safe
Arginine isoform pathways.
The L-arginine-nitric-oxide signaling pathway is probably the most
complicated facet of biochemistry. In creating an efficacious formula,
the form of L-arginine used will dictate the quality of the product.
If the form of Arginine used in a
formula is not appropriate, the product will not work, and
can exhibit side effects.
The L-form (left-handed) of Arginine is acceptable for human use,
while the D-form (right-handed) is not. The D-form of L-arginine
is an example of an unacceptable form of L-arginine, though there
are many other unacceptable forms, including L-arginine antagonists.
Antagonists
are agents that directly compete with L-arginine and: |
| •
|
Block
L-arginine health benefits |
| • |
Prevent
L-arginine metabolism |
| •
|
Negate L-arginine’s ability to cross the Blood-Brain-Barrier |
| •
|
Cause
potential serious health problems (including damage to sperm
and mortality) |
|
 |
Arginine
HCL
In studies where the HCL form of L-arginine has been used, metabolic
acidosis and alterations in electrolytes have been documented. It
is therefore not recommended for human use. Arginine HCL is the
form that was used in the tragic Johns Hopkins/JAMA clinical trial
that caused mortalities.
Arginine Pyroglutamate
Not recommended for human use. Mechanism of action in the body is
entirely speculative according to the Physician’s Desk Reference
(PDR).
Arginine Ketoglutarate And Alpha-Ketoglutarate (AKG)
Researchers and physicians caution that Alpha-ketoglutarate is not
recommended for human use.
High Glycemic L-Arginine
High glycemic L-arginine formulas are not eff ective and are contraindicated
for use in humans. High glycemic formulas include those that contain:
maltodextrins, glucose, glucose polymers, sugar (sucrose), honey,
high fructose corn syrup, fructose corn syrup, flavors made with
maltodextrins, sweeteners without caloric impact, and any high glycemic
raw material. Any of these ingredients block Arginine transport
and metabolism and are contraindicated in L-arginine formulas.
Nutrients & Supplements
Foods, drinks (other than water), nutrients, vitamins, herbs, minerals,
and supplements also block L-arginine. Therefore, they must be taken
separately from L-arginine formulas. |
Capsules,
Tablets, Sprays, Liquids, Gels
L-Arginine formulas are not effective
in capsule, tablet, spray, liquid, and/or gel forms.
The delicate nature of L-arginine, and its specific isoform pathways
in the body, do not allow for transport when entrapped in a gel
or a liquid, or a capsule or tablet.
Dosage
Formulas containing Less Than 5,000 Mg (5 grams) of elemental L-arginine
DO NOT WORK.
In terms of sports performance, muscle-building, and anti-aging,
L-arginine formulas containing less than 10,000 Mg (10 grams) of
elemental L-arginine DO NOT WORK.
The minimum therapeutic dosage of L-arginine is 5,000 mg.
Formulas
Without A Blind Amino Acid Rider
L-arginine formulas that do not contain a Blind Amino Acid Rider
DO NOT WORK.
Formulas That Contain Protein Or Any Competing Amino
Acid
L-arginine formulas that contain other amino acids, like L-Lysine
or L-Citrulline, DO NOT WORK.
L-arginine formulas that contain any form of protein DO NOT WORK.
L-LYSINE & L-ARGININE
Formulas
containing L-arginine with
L-lysine do not work, and are the result of improper
formulating.
Dietary
disproportions of amino acids are counterproductive and can alter
serum levels and flux of specific amino acids across the Blood-Brain-Barrier
(BBB). The Lysine/Arginine antagonism is an example of this alteration.
A plethora of definitive clinical studies have proven that L-arginine
and L-lysine are antagonistic in humans, IE Johns Hopkins University.
One
of the most prominent formulating mistakes related to L-arginine
antagonism is the inclusion of Lysine. Though L-lysine is a direct
antagonist of L-arginine, it is frequently seen in L-arginine formulas.
L-lysine should never be combined with L-arginine, but is often
seen in L-arginine products with the purpose of mitigating the herpes
reaction. This combining technique is a result of bad science, as
it negates the benefits of L-arginine.
L-LYSINE
& HERPES SIMPLEX VIRUS
The
human Herpes Simplex Virus (HSV) is a recurrent viral infection
that is caused by Herpes virus hominis (HVH), a widespread infectious
agent. The human herpes viruses are multipotential, and inclu+de
HSV types 1 and 2, human cytomegalovirus, Varicella-Zoster virus,
and the Epstein-Barr Virus. These viruses are transmitted by respiratory
and oral secretions and commonly produce fever blisters, cold sores,
flu-like symptoms, headache, swollen glands, and may also infect
the urethra causing burning sensations during urination. There is
currently no cure for HSV, but there are measures that can be taken
to reduce manifestations.
Increased
levels of lysine over arginine suppress viral replication and inhibit
cytopathogenicity of herpes simplex virus (HSV). This interaction
between the amino acids lysine and arginine can be mitigated by
taking L-lysine supplements about 2 hours separately from L-arginine
Improperly
formulated L-ARGININE will trigger herpes simplex symptoms in humans.
L-arginine
can be formulated with a Blind Amino Acid Rider to mitigate
or eliminate the reactivation caused by oral ingestion of L-arginine,
but the effects of herpes simplex is also triggered in humans by
lack of sleep and stress.
Eight
hours of sleep per night is required to reduce activation of HSV.
During human sleep cycles, immune function is activated, which affects
the herpes simplex virus, as well as all viruses. Additionally,
if sleep cycles and nutrient intake is not balanced, HSV will become
prominent with manifestations such as cold sores and lethargy.
Eight hours of sleep per night is required to reduce activation
of HSV. During human sleep cycles, immune function is activated,
which affects the herpes simplex virus, as well as all viruses.
Additionally, if sleep cycles and nutrient intake is not balanced,
HSV will become prominent with manifestations such as cold sores
and lethargy.
L-LYSINE
DOSAGE & HSV
Lysine
has been used effectively as an agent for reduction of occurrence,
severity and healing time for recurrent HSV infection. Supplementation
with free-form L-lysine has shown to be beneficial in controlling
herpes symptoms.
The
amount of Lysine required to control herpes varies from case to
case, but a typical dose to maintain remission (as stated in most
trials) is 500-1000 milligrams (mg), and for active herpes, 1000
mg (1 gram) to 6000 mg (6 grams) taken daily.
Clinical
trials suggested that persons with the herpes simplex virus take
1000 mg of oral L-lysine in capsule form, a few times per day (1-3),
taken 2 hours apart from the L-arginine (as they compete with each
other).
In
terms of controlling HSV outbreaks, UCLA School of Medicine (Dr.
Griffith, Dr. Kagan, Dr. Norins) found that there is a 96% success
rate in patients taking 1500 mg of supplemental L-lysine daily.
Lysine
supplements in capsule form can be found in most health food stores.
When selecting a Lysine supplement, Lysine should be the only ingredient
listed on the label, as the addition of any other amino acid or
ingredient can negate its benefit. Tablets and gels are to be avoided.
Aspirin
Aspirin is a known antagonist to Arginine, and cannot be taken within
2 hours of taking L-arginine. Aspirin can be beneficial and is frequently
recommended by a physician. If your physician has recommended aspirin,
take it separately from L-arginine. |
L-Ornithine
L-ornithine has been clinically proven to be an antagonist of L-arginine
and disrupts Larginine transport. L-ornithine is contraindicated
in any L-arginine formulas, and specifically in products geared
to the athlete. L-ornithine should be avoided by bodybuilders, powerlifters,
and all other athletes, as well as persons desiring to increase
muscle mass, because Ornithine is a non-protein amino acid. Ornithine
is not anabolic and is not used to make protein in the human body,
whereas Arginine does make protein and is anabolic.
L-Citrulline
According to multiple independent studies, L-citrulline is not an
appropriate ingredient in an L-arginine formulation. The use of
Citrulline in an L-arginine formulation can cause inherent problems,
including depletion of L-arginine.
| • |
Endogenous
NOS inhibitors reduce the enzyme sensitivity to L-arginine.
These inhibitors include, NG, NG-dimethyl-L-arginine, L-citrulline,
argininosuccinic acid and agmatine. |
| • |
Intracellular
L-citrulline, an NOS product, is a potent inhibitor of NOS
so that the cells may need extra L-arginine to compete with
L-citrulline inhibition. |
The Arginine Paradox (Folia Pharmacol. Japan Vol.
119 7-14:2002 Department of Pharmacology, Teikyo University School
of Medicine):
Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational
control of inducible nitric oxide synthase expression by Arginine
can explain the Arginine paradox. Proc Natl Acad Sci U S A 2003;100:4843-8.
P. Roy. Recent trends in the nitrergic nervous system.2005. In.
Journal of Pharmacology; P. Roy, G. Venkat Ramana, M. Naidu, P.
Usha Rani
Thomas G, Ramwell PW. Nitric oxide, donors and inhibitors. In: Bertram
G Katzung, editor. Basic and Clinical Pharmacology. United States:
McGraw Hill; 2004.p.313-8.
Chandran S, Sridhar N, Veeranjaneyulu A. Nitric oxide: concepts,
current perspectives and future therapeutic implications. Indian
J Pharmacol 1998;30:351-66.
|
 |
| • |
Capsules
Or Tablets |
| • |
Sprays
Or Liquid |
| • |
High
Glycemic Formulas (Any Formula That Contains Glucose, Glucose
Polymers, Sugar, Sucrose, Maltodextrins, Honey) |
| • |
Less
Than 10,000 Mg (10 G) Of Elemental L-Arginine |
| • |
Formulas
Without A Blind Amino Acid Rider |
| • |
Formula
That Contain Protein Or Competing Amino Acids |
| • |
Formulas
With No/Low Carbohydrates |
| • |
HCL
Arginine Or |
| • |
Formulas
Taken At Incorrect BBB Access-Times |
| • |
Formulas
Taken With Or Near Food/Drink (Other Than Water) |
| • |
Formulas
That Contain High Glycemic Flavor Systems |
| • |
L-Lysine:
Unlike L-arginine, L-lysine does not improve whole muscle
strength or size, and is therefore a substandard amino acid for athletes
and
persons desiring to increase size and power output from muscle tissue
and
muscle mitochondria. |
References
& Bibliography |
NIH
Announces Nanomedicine Development Center Awards. www.Nano.gov
J Cell Biochem.2006 Jan 26; Engineered nanoparticles as precise
drug delivery systems. Wikipedia. 2006
Angew Chem Int Ed Engl.2005 Feb 11;44(8):1166-81; DNA CODES FOR
NANOSCIENCE
Samori B, et al
Nano Lett.,6(4),587-591,2006.American Chemical Society.Covalently
Linked Au Nanoparticles to
a Viral Vector: Potential for Combined Photothermal and Gene Cancer
Therapy.Maaike Everts et al
Pascual et al. May 2004. “GLUT1 deficiency and other glucose
transporter diseases”. European
journal of endocrinology 150 (5): 627-33.
Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Development
of a computational approach to
predict blood-brain barrier permeability. Drug Metab. Dispos. 2004,
32, 132-9.
Klepper, J, Voit T (June 2002). “Facilitated glucose transporter
protein type 1 (GLUT1) deficiency
syndrome: impaired glucose transport into brain-- a review”.
European journal of pediatrics 161 (6):
295-304.
Reichel, A.; Begley, D. J.; Abbott, N. J. An overview of in vitro
techniques for blood-brain barrier
studies. Methods Mol. Med. 2003, 89, 307-24.
Abbott Joan, N. Prediction of blood-brain barrier permeation in
drug discovery from in vivo, in vitro
and in silico models. Drug Discovery Today: Technol. 2004, 1, 407-416.
Crivori, P.; Cruciani, G.; Carrupt, P. A.; Testa, B. Predicting
blood-brain barrier permeation from
three-dimensional molecular structure. J. Med. Chem. 2000, 43, 2204-16.
Basak, S.; Gute, B. D.; Drewes, L. R. Predicting blood-brain transport
of drugs: a computational approach. Pharm. Res. 1996, 13, 775-8.
Keseru, G. M.; Molnar, L. High-throughput prediction of blood-brain
partitioning: a thermodynamic
approach. J. Chem. Inf. Comput. Sci. 2001, 41, 120-8.
Hutter, M. C. Prediction of blood-brain barrier permeation using
quantum chemically derived information. J. Comput.-Aided Mol. Des.
2003, 17, 415-33. |
Copyright © 2006-2009
No copies of this material may be made in any format whatsoever
(including electronic) without express prior written permission
from the authors. |
|
